Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924289 | 0.88 | TSHR (0.52) | TSHRCNR1CASP2MCL1KDM4E | |
| SCHEMBL13398413 | 0.88 | TSHR (0.52) | TSHRCNR1CASP2MCL1KDM4E | |
| SCHEMBL30781826 | 0.88 | TSHR (0.52) | TSHRCNR1CASP2MCL1KDM4E | |
| SCHEMBL13498639 | 0.88 | TSHR (0.71) | TSHRCNR1CASP2KDM4ELMNA | |
| SCHEMBL12015109 | 0.88 | TSHR (0.66) | TSHRCNR1CASP2KDM4ELMNA | |
| SCHEMBL10311848 | 0.86 | CASP2 (0.66) | TSHRCNR1CASP2HPGDNAAA | |
| SCHEMBL20323905 | 0.85 | TSHR (0.58) | TSHRCNR1CASP2KDM4ELMNA | |
| SCHEMBL19588536 | 0.84 | TSHR (0.67) | TSHRCNR1CASP2KDM4ELMNA | |
| SCHEMBL15441011 | 0.84 | CASP2 (0.69) | TSHRCNR1CASP2NAAAFAAH | |
| SCHEMBL1569763 | 0.83 | TSHR (0.59) | TSHRCNR1KDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025005010-A1 | CURED FILM AND ORGANIC EL DISPLAY DEVICE | 東レ株式会社 | 2025-01-02 | — | — | WO | disclosed |
| WO-2023001186-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | 派格生物医药(苏州)股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-15 | — | — | US | disclosed |
| EP-3728235-B1 | SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2021-03-25 | — | — | US | disclosed |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180000962-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9522194-B2 | Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9353150-B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-31 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120141510-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120094232-A1 | PRODUCTION METHOD OF POLYHYDROXYIMIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7994135-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | TSHR 2609/4885CNR1 3998/4885CASP2 4231/4885 |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | TSHR 3534/4885CNR1 4849/4885CASP2 2510/4885 |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | UNG, TYMP, TYMS | TSHR 901/4885CNR1 3997/4885CASP2 2972/4885 |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | TSHR 901/4885CNR1 3997/4885CASP2 2972/4885 |
| US-20180000962-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | LNPEP, ALB, GSTP1 | TSHR 1803/4885CNR1 2838/4885CASP2 4106/4885 |
| US-20120141510-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | TSHR 2609/4885CNR1 3998/4885CASP2 4231/4885 |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | PRLHR, GHRHR, TRHR | TSHR 5/4885CNR1 342/4885CASP2 4803/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | TSHR 1082/4885CNR1 159/4885CASP2 2377/4885 |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | TSHR 2609/4885CNR1 3998/4885CASP2 4231/4885 |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | TSHR 2609/4885CNR1 3998/4885CASP2 4231/4885 |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | TSHR 2609/4885CNR1 3998/4885CASP2 4231/4885 |
| US-20120094232-A1 | PRODUCTION METHOD OF POLYHYDROXYIMIDE | GRHPR, MRPL21, F12 | TSHR 1032/4885CNR1 2451/4885CASP2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.